CYP2D6 and Alzheimer disease: The results showed no associations between CYP2D6 IM/PM metabolizer status and switching (OR [95% CI]: 1.34 [0.89–2.02]) or discontinuing (OR [95% CI]: 1.47 [0.85–2.52]) AD treatment.